Skip to main content
Top
Published in: International Urology and Nephrology 2/2012

01-04-2012 | Nephrology – Original Paper

Obstructive sleep apnea syndrome is related to the progression of chronic kidney disease

Authors: Asiye Kanbay, Hakan Buyukoglan, Nezihe Ozdogan, Elif Kaya, Fatma Sema Oymak, Inci Gulmez, Ramazan Demir, Oguz Kokturk, Adrian Covic

Published in: International Urology and Nephrology | Issue 2/2012

Login to get access

Abstract

Background and aim

Obstructive sleep apnea syndrome (OSAS) is an independent risk factor for the development of cardiovascular events and hypertension. The possible causes are oxygen desaturation due to hypopnea, increased cytokine levels and insulin resistance. All these risk factors also have a role in the progression of chronic kidney disease (CKD). The aim of this study was to determine the relationship between OSAS and the severity of CKD.

Materials and methods

We retrospectively evaluated the medical records of 175 subjects who were admitted for the polysomnography study. OSAS was diagnosed by polysomnography if Apnea-Hypopnea Index (AHI) > 5 and glomerular filtration rate (GFR) was calculated with Cockcroft–Gault formula. According to AHI, individuals with AHI < 5 were recruited as group 1 (OSAS negative group), those with AHI = 5–15 group 2 (mild OSAS group), those with AHI = 15–30 group 3 (moderate OSAS group), and those with AHI > 30 group 4 (severe OSAS group).

Results

Of the subjects, 117 (67%) were men, 58 (33%) were women and the mean age was 54.0 ± 12.1 years. There were 28 (14.3%), 18 (10.3%), 35 (20.0%) and 97 (55.4%) patients in groups 1, 2, 3 and 4 respectively. The prevalence of diabetes mellitus and hypertension and body mass index was significantly higher in severe OSAS group (P < 0.05). A significant decrease in GFR was detected when the severity of OSAS increased (group 1 = 50.0 ± 11.8, group 2 = 44.8 ± 15.9, group 3 = 40.8 ± 14.7, group 4 = 38.8 ± 16.0; P for trend < 0.001).

Conclusion

In the light of the present study, we speculate that OSAS is an independent risk factor for the progression of chronic kidney disease, which is a growing health problem. Further randomized-multicenter prospective studies are warranted to evaluate this relationship.
Literature
1.
go back to reference Weiss JW, Launois SH, Anand A, Garpestad E (1999) Cardiovascular morbidity in obstructive sleep apnea. Prog Cardiovasc Dis 41:367–376PubMedCrossRef Weiss JW, Launois SH, Anand A, Garpestad E (1999) Cardiovascular morbidity in obstructive sleep apnea. Prog Cardiovasc Dis 41:367–376PubMedCrossRef
2.
go back to reference Yang WS, Lee WJ, Funahashi T et al (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815–3819PubMedCrossRef Yang WS, Lee WJ, Funahashi T et al (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815–3819PubMedCrossRef
3.
go back to reference Hallett M, Burden S, Stewart D, Mahony J, Farrell P (1995) Sleep apnea in end-stage renal disease patients on hemodialysis and continuous ambulatory peritoneal dialysis. ASAIO J 41:M435–M441PubMedCrossRef Hallett M, Burden S, Stewart D, Mahony J, Farrell P (1995) Sleep apnea in end-stage renal disease patients on hemodialysis and continuous ambulatory peritoneal dialysis. ASAIO J 41:M435–M441PubMedCrossRef
4.
go back to reference Kimmel PL, Miller G, Mendelson WB (1989) Sleep apnea syndrome in chronic renal disease. Am J Med 86:308–314PubMedCrossRef Kimmel PL, Miller G, Mendelson WB (1989) Sleep apnea syndrome in chronic renal disease. Am J Med 86:308–314PubMedCrossRef
5.
go back to reference Kraus MA, Hamburger RJ (1997) Sleep apnea in renal failure. Adv Perit Dial 13:88–92PubMed Kraus MA, Hamburger RJ (1997) Sleep apnea in renal failure. Adv Perit Dial 13:88–92PubMed
6.
go back to reference Kuhlmann U, Becker HF, Birkhahn M et al (2000) Sleep-apnea in patients with end-stage renal disease and objective results. Clin Nephrol 53:460–466PubMed Kuhlmann U, Becker HF, Birkhahn M et al (2000) Sleep-apnea in patients with end-stage renal disease and objective results. Clin Nephrol 53:460–466PubMed
7.
go back to reference Yamauchi M, Nakano H, Maekawa J et al (2005) Oxidative stress in obstructive sleep apnea. Chest 127:1674–1679PubMedCrossRef Yamauchi M, Nakano H, Maekawa J et al (2005) Oxidative stress in obstructive sleep apnea. Chest 127:1674–1679PubMedCrossRef
8.
go back to reference Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187PubMedCrossRef Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187PubMedCrossRef
9.
go back to reference Rechtschaffen A (1968) A manual of standardized terminology, techniques, and scoring system for sleep stages in human subjects. VCLA, Los Angeles Rechtschaffen A (1968) A manual of standardized terminology, techniques, and scoring system for sleep stages in human subjects. VCLA, Los Angeles
10.
go back to reference EEG arousals (1992) Scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 15:173–184 EEG arousals (1992) Scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 15:173–184
11.
go back to reference Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545PubMed Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545PubMed
12.
go back to reference Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038–2047PubMedCrossRef Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038–2047PubMedCrossRef
14.
go back to reference de Oliveira Rodrigues CJ, Marson O, Tufic S et al (2005) Relationship among end-stage renal disease, hypertension, and sleep apnea in nondiabetic dialysis patients. Am J Hypertens 18:152–157PubMedCrossRef de Oliveira Rodrigues CJ, Marson O, Tufic S et al (2005) Relationship among end-stage renal disease, hypertension, and sleep apnea in nondiabetic dialysis patients. Am J Hypertens 18:152–157PubMedCrossRef
15.
go back to reference Millman RP, Kimmel PL, Shore ET, Wasserstein AG (1985) Sleep apnea in hemodialysis patients: the lack of testosterone effect on its pathogenesis. Nephron. 40:407–410PubMedCrossRef Millman RP, Kimmel PL, Shore ET, Wasserstein AG (1985) Sleep apnea in hemodialysis patients: the lack of testosterone effect on its pathogenesis. Nephron. 40:407–410PubMedCrossRef
16.
go back to reference Fein AM, Niederman MS, Imbriano L, Rosen H (1987) Reversal of sleep apnea in uremia by dialysis. Arch Intern Med 147:1355–1356PubMedCrossRef Fein AM, Niederman MS, Imbriano L, Rosen H (1987) Reversal of sleep apnea in uremia by dialysis. Arch Intern Med 147:1355–1356PubMedCrossRef
17.
go back to reference Beecroft J, Duffin J, Pierratos A, Chan CT, McFarlane P, Hanly PJ (2006) Enhanced chemo-responsiveness in patients with sleep apnoea and end-stage renal disease. Eur Respir J 28:151–158PubMedCrossRef Beecroft J, Duffin J, Pierratos A, Chan CT, McFarlane P, Hanly PJ (2006) Enhanced chemo-responsiveness in patients with sleep apnoea and end-stage renal disease. Eur Respir J 28:151–158PubMedCrossRef
18.
go back to reference Auckley DH, Schmidt-Nowara W, Brown LK (1999) Reversal of sleep apnea hypopnea syndrome in end-stage renal disease after kidney transplantation. Am J Kidney Dis 34:739–744PubMedCrossRef Auckley DH, Schmidt-Nowara W, Brown LK (1999) Reversal of sleep apnea hypopnea syndrome in end-stage renal disease after kidney transplantation. Am J Kidney Dis 34:739–744PubMedCrossRef
19.
go back to reference Hanly PJ, Pierratos A (2001) Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 344:102–107PubMedCrossRef Hanly PJ, Pierratos A (2001) Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 344:102–107PubMedCrossRef
20.
go back to reference Dursunoglu N, Dursunoglu D (2005) Obstructive sleep apnea syndrome, endothelial dysfunction and coronary atherosclerosis. Tuberk Toraks. 53:299–306PubMed Dursunoglu N, Dursunoglu D (2005) Obstructive sleep apnea syndrome, endothelial dysfunction and coronary atherosclerosis. Tuberk Toraks. 53:299–306PubMed
21.
go back to reference Schulz R, Hummel C, Heinemann S, Seeger W, Grimminger F (2002) Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med 165:67–70PubMed Schulz R, Hummel C, Heinemann S, Seeger W, Grimminger F (2002) Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med 165:67–70PubMed
22.
go back to reference Sim JJ, Rasgon SA, Kujubu DA et al (2009) Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohort. Chest 135:710–716PubMedCrossRef Sim JJ, Rasgon SA, Kujubu DA et al (2009) Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohort. Chest 135:710–716PubMedCrossRef
Metadata
Title
Obstructive sleep apnea syndrome is related to the progression of chronic kidney disease
Authors
Asiye Kanbay
Hakan Buyukoglan
Nezihe Ozdogan
Elif Kaya
Fatma Sema Oymak
Inci Gulmez
Ramazan Demir
Oguz Kokturk
Adrian Covic
Publication date
01-04-2012
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2012
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-011-9927-8

Other articles of this Issue 2/2012

International Urology and Nephrology 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.